Pharmaceutical Law & Industry Report® Table of Cases

Magers v. Matrixx Initiatives Inc. (M.D.N.C.), 239
Maher, U.S. ex rel. v. Ortho-McNeil Pharm. Inc. (D. Mass.), 585
Mallinckrodt Inc. v. Watson Labs. Inc. (D.N.J.), 1621
Mason v. SmithKlineBeecham Corp. (7th Cir.), 271
Massachusetts v. Mylan Labs. (D. Mass.), 208; 314; 1274; 1430; 1613
Matrix Labs. Ltd.; Daiichi Sankyo Co. v. (Fed. Cir.), 1175
Matrixx Initiatives Inc.; Campbell v. (D. Idaho), 239
Matrixx Initiatives Inc.; Cooper v. (D. Idaho), 239
Matrixx Initiatives Inc.; Henderson v. (D. Idaho), 239
Matrixx Initiatives Inc.; Magers v. (M.D.N.C.), 239
Matrixx Initiatives Inc.; Moore v. (D. Idaho), 239
Matrixx Initiatives Inc. v. Siracusano (U.S., rev grant), 856; (amicus brief filed), 1143; 1470
Maxwell-Jolly; California Pharmacists Ass'n v. (9th Cir.), 319
Mayo Collaborative Servs. v. Prometheus Labs. Inc. (U.S., brief filed), 83; (rem), 851; (Fed. Cir.), 1608
Mays v. Bayer Corp. (8th Cir.), 61
McAdam; U.S. v. (D. Mont.), 1346
McCarrell v. Hoffmann-LaRoche Inc. (N.J. Super. Ct.), 238
McClain v. Pfizer Inc. (D. Conn.), 458
McGraw, West Virginia ex rel. v. Johnson & Johnson (W. Va.), 1501
McKee, U.S. ex rel. v. Novartis Pharms. Corp. (E.D. Pa.), 1269
McKesson Corp.; Wisconsin ex rel. Hagens Berman Sobol Shapiro LLP v. (Wis. Cir. Ct.), 1622
McKesson Governmental Entities Average Wholesale Price Litig., In re (D. Mass.), 1340
McNeil Consumer Specialty Pharms.; Lofton v. (N.D. Tex.), 157
Meade v. Wyeth Inc. (S.D.W. Va.), 1554
Medicines Co. v. Hospira Inc. (D. Del.), 1144
Medicines Co. v. Kappos (E.D. Va.), 154; 350; 713; 1050
Medicis Pharm. Corp. v. Mylan Inc. (D. Del.), 976
Medicis Pharm. Corp. v. Ranbaxy Pharms. Inc. (D. Del.), 622
Medicis Pharm. Corp. Sec. Litig., In re (D. Ariz.), 15
Meharg v. I-Flow Corp. (S.D. Ind.), 321
Meijer Inc.; Ferring B.V. v. (U.S., rev den), 852
Mensing; Actavis Elizabeth LLC v. (U.S., rev sought), 677; (brief filed), 1428; (rev grant), 1577
Mensing; Pliva Inc. v. (U.S., rev sought), 677; (brief filed), 1428; (rev grant), 1577
Merck & Co.; Apotex Inc. v. (Canada, Fed. Ct.), 502
Merck & Co.; Boles v. (S.D.N.Y.), 421; 855; 1344
Merck & Co.; Cain v. (N.J. Super. Ct. App. Div.), 1147
Merck & Co.; Dier v. (5th Cir.), 983
Merck & Co.; Flemings v. (2d Cir.), 1466
Merck & Co.; Graves v. (S.D.N.Y.), 1509
Merck & Co.; Koor v. (S.D.N.Y.), 624
Merck & Co.; Louisiana Wholesale Drug Co. v. (D. Del.), 316
Merck & Co. v. Minister of Health (Canada, Fed. Ct.), 1445
Merck & Co. v. Reynolds (U.S.), 554
Merck Sharpe & Dohme (Aust) Pty Ltd.; Peterson v. (Australia, Fed. Ct.), 372
Metoprolol Succinate Direct Purchaser Antitrust Litig., In re (D. Del.), 515
Millennium Pharms. Inc. v. Teva Parenteral Medicines Inc. (D. Del.), 551
Miller v. SmithKlineBeecham Corp. (10th Cir.), 744
Mills; IMS Health Inc. v. (1st Cir.), 1049
Minister of Health; Apotex v. (Canada, Fed. Ct. App.), 1638
Minister of Health; Janssen-Ortho Inc. v. (Canada, Fed. Ct.), 693
Minister of Health; Merck & Co. v. (Canada, Fed. Ct.), 1445
Minister of Health; Novopharm Ltd. v. (Canada, Fed. Ct.), 761
Minnesota Pharmacists Ass'n v. Pawlenty (D. Minn.), 234; 484
Mississippi v. Bayer Corp. (Miss.), 517
Mississippi, Hood ex rel. v. AstraZeneca Pharms. LP (N.D. Miss.), 1343
Mitsubishi Chem. Corp. v. Barr Labs. Inc. (S.D.N.Y.), 810
Momenta Pharms. Inc. v. Teva Pharm. Indus. Ltd. (D. Mass.), 1550
Montgomery v. Wyeth (U.S., rev den), 418
Moore v. Matrixx Initiatives Inc. (D. Idaho), 239
Morris v. Wyeth Inc. (6th Cir.), 916; 1501
Mosley v. Wyeth Inc. (S.D. Ala.), 557
Muecke Co. v. CVS Caremark Corp. (S.D. Tex.), 1307
Mutual Pharm. Co.; Bartlett v. (D.N.H.), 986; 1183
Mutual Pharm. Co.; Tyco Healthcare Group LP v. (D.N.J.), 586
Mutual Pharm. Co. v. Watson Pharms. Inc. (D.N.J.), 199; 314; 1397
Mylan Inc.; Arnett v. (S.D.W. Va.), 718
Mylan Inc. v. Boehringer Ingelheim Intl. GmbH (W.D. Pa.), 413
Mylan Inc.; Cruz v. (M.D. Fla.), 279
Mylan Inc. v. Daiichi Sankyo Co. (U.S., rev sought), 1615
Mylan Inc.; Frisby-Cadillo v. (N.D. Cal.), 650
Mylan Inc.; LaPaglia v. (N.D. Ohio), 280
Mylan Inc.; Medicis Pharm. Corp. v. (D. Del.), 976
Mylan Inc.; Shionogi Pharma Inc. v. (D. Del.), 1620
Mylan Inc. v. SmithKlineBeecham Corp. (D.N.J.), 1340; 1395
Mylan Inc.; Stanley v. (D. Utah), 1248
Mylan Inc.; Turner v. (E.D. Mo.), 555
Mylan Labs.; Massachusetts v. (D. Mass.), 208; 314; 1274; 1430; 1613
Mylan Pharms. Inc.; AstraZeneca Pharms. LP v. (D. Del.), 643
Mylan Pharms. Inc.; Boehringer Ingelheim Intl. GmbH v. (D.N.J.), 1106
Mylan Pharms. Inc.; Bristol-Myers Squibb Co. v. (D. Del.), 123
Mylan Pharms. Inc.; Novo Nordisk A/S v. (D.N.J.), 483
Mylan Pharms. Inc.; Pfizer Inc. v. (D. Del.), 207
Mylan Pharms. Inc.; Research Found. of State Univ. of N.Y. v. (D. Del.), 887
Mylan Pharms. Inc.; Schering-Plough Corp. v. (D.N.J.), 7; 780